Portfolio news Archives - Page 4 of 7

Engimmune Therapeutics raises $16.7M in seed financing co-led by Pureos Bioventures and Novo Holdings

Engimmune is a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, founded in August 2021 by Dr. Rodrigo Vazquez-Lombardi, Prof Sai Reddy and Dr…

Arianna03.05.2022

All Portfolio news

Cimeio Therapeutics raises a 50M USD series A financing from Versant Ventures

Cimeio therapeutics is a spin-off from the University of Basel. The scientific basis was born out of years of cutting-edge research by Professor Lukas Jeker–co-founder…

Arianna13.04.2022

All Portfolio news

BaseLaunch – onwards and upwards

2022 started off on some good notes for BaseLaunch, with two new companies (one still in stealth) joining our portfolio and another one announcing the…

Arianna28.02.2022

All Portfolio news

Aukera Therapeutics joins BaseLaunch Portfolio

We are excited to welcome Aukera Therapeutics as our newest portfolio company! Basel, Switzerland., 15 February 2022 — Aukera Therapeutics is a spin-off from the Biozentrum…

Arianna15.02.2022

All Portfolio news

Stromal Therapeutics joins BaseLaunch Portfolio

We are excited to welcome Stromal Therapeutics as our newest portfolio company! Basel, Switzerland., 28 January 2022 — Stromal Therapeutics is emerging from one of…

Arianna28.01.2022

Alentis starts first in-human clinical trial

All Portfolio news

Alentis Therapeutics starts their first-in-human clinical trial

FDA greenlights Alentis Phase 1 protocol study design Alentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 — Alentis Therapeutics, AG…

clement06.01.2022

Anaveon_-startups_Switzerland-credit-Jasmin-Rei

All Portfolio news

Anaveon raises 110 Million Swiss francs in Series B financing

Back in 2017, when we first met Andreas Katopodis, he had the vision to build a company that translates breakthrough science in the field of…

clement17.12.2021

All Portfolio news

Engimmune Therapeutics joins BaseLaunch Portfolio

Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on…

clement26.10.2021

All Portfolio news

Expansion of BaseLaunch portfolio of companies 2021

We are proud to announce the recent expansion of our portfolio of companies. We welcome two newcomers - Incephalo and NextImmune - to our family.…

clement23.06.2021

All Portfolio news

Alentis secures $67 Million US dollars

Looking back, what a journey! We remember well when we first started working with Thomas Baumert in late 2017. Built on many years of transformational…

clement21.06.2021

Portfolio news

Engimmune Therapeutics raises $16.7M in seed financing co-led by Pureos Bioventures and Novo Holdings

Cimeio Therapeutics raises a 50M USD series A financing from Versant Ventures

BaseLaunch – onwards and upwards

Aukera Therapeutics joins BaseLaunch Portfolio

Stromal Therapeutics joins BaseLaunch Portfolio

Alentis Therapeutics starts their first-in-human clinical trial

Anaveon raises 110 Million Swiss francs in Series B financing

Engimmune Therapeutics joins BaseLaunch Portfolio

Expansion of BaseLaunch portfolio of companies 2021

Alentis secures $67 Million US dollars

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us